Skip to main content

Hospital Business

Innovative solutions for patient health

The Consilient Health Hospital Division was established in 2016 and has since grown into a prominent supplier within the hospital generics market. With comprehensive access across NHS hospitals, private hospital groups, commercial compounding companies, home care providers, and clinical trial suppliers throughout the UK, Consilient Health continues to expand its presence and influence.

Holding numerous NHS contracts, Consilient Health is a trusted provider of essential pharmaceuticals across various specialties, including Oncology, Microbiology, Psychiatry, Cardiology, Renal Medicine, Maternity, Urology and Endocrinology. Our robust and agile supply chain allows us to swiftly respond to market demands, ensuring consistent product availability and reliability.

Committed to ongoing innovation, Consilient Health consistently broadens its portfolio by introducing value-added generics, enhancing therapeutic outcomes, and delivering cost-effective solutions to our healthcare partners.

For access to the summary of product characteristics, patient information leaflets and available risk minimisation measures, please view the product section below.

Visit consilienthealth.com for more information

consilienthealth.com

Products

We work with a broad range of pharmaceutical companies to develop and licence generic products for the UK market. Our product portfolio comprises of generic drugs for injectable and infusion treatments as well as solid dose medicines. We are constantly working with our partners on introducing new products to our portfolio.

Hospital generic products available in the UK:

  • Carbetocin 100mcg Solution for Injection, 5 PFS
    SPC PIL
  • Cefuroxime 50 mg powder for solution for injection, 10 vials
    SPC PIL
  • Vinorelbine 20mg, soft capsule 1
    SPC PIL
  • Vinorelbine 30mg, soft capsule 1
    SPC PIL
  • Vinorelbine 80mg, soft capsule 1
    SPC PIL

Share this page


Code No: UK-CH-475(12)
Date of Preparation: March 2025